Skip to main content
[Preprint]. 2023 Jan 10:2023.01.09.523323. [Version 1] doi: 10.1101/2023.01.09.523323

Fig. 1: Aclarubicin blocks growth and causes gains in RNA pol II ser2P.

Fig. 1:

(A) Experimental design. The four treatments were 1μM Doxorubicin (doxo), 5μM actinomycin D (Act D)1μM aclarubicin (acla) and mock-treated (DMSO) control (B) Cell numbers at 0 hour and at 24 hours. (C) Heatmap aligned to TSS of all promoters showing paused polymerase spike-normalized signal under each treatment condition. (D) Representative UCSC browser track snapshot of paused RNA Pol II distribution. (E) Heatmap aligned to the transcriptional start site (TSS) of all promoters showing spike-normalized elongating polymerase signal under each treatment condition. (F) Representative UCSC browser track snapshot of elongating polymerase distribution.